AbbVie (ABBV) Other Non-Current Liabilities (2012 - 2026)
AbbVie (ABBV) reported Other Non-Current Liabilities of $34.1 billion for Q1 2026, up 50.18% year-over-year from $22.7 billion in Q1 2025, and up 4.73% on a QoQ basis from $32.6 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Other Non-Current Liabilities data on file, last reported at $34.1 billion in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 50.18% year-over-year to $34.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.1 billion (up 50.18% YoY) and the FY2025 annual result came in at $32.6 billion, up 50.32% from the prior year.
- Other Non-Current Liabilities rose to $34.1 billion in Q1 2026 per ABBV's latest filing, from $32.6 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $34.1 billion in Q1 2026 and bottomed at $13.8 billion in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $20.2 billion (2024), against an average of $22.0 billion.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities fell 2.43%; it then surged 51.49% in 2025.
- Tracing ABBV's Other Non-Current Liabilities over 5 years: stood at $16.4 billion in 2022, then grew by 21.4% to $19.9 billion in 2023, then rose by 8.93% to $21.7 billion in 2024, then surged by 50.32% to $32.6 billion in 2025, then increased by 4.73% to $34.1 billion in 2026.
- Per Business Quant, the three latest ABBV Other Non-Current Liabilities figures stand at $34.1 billion (Q1 2026), $32.6 billion (Q4 2025), and $31.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.11 Bn |
| Dec 31, 2025 | 32.57 Bn |
| Sep 30, 2025 | 31.66 Bn |
| Jun 30, 2025 | 32.04 Bn |
| Mar 31, 2025 | 22.71 Bn |
| Dec 31, 2024 | 21.67 Bn |
| Sep 30, 2024 | 21.93 Bn |
| Jun 30, 2024 | 21.15 Bn |
| Mar 31, 2024 | 20.16 Bn |
| Dec 31, 2023 | 19.89 Bn |
| Sep 30, 2023 | 18.67 Bn |
| Jun 30, 2023 | 19.15 Bn |
| Mar 31, 2023 | 17.93 Bn |
| Dec 31, 2022 | 16.38 Bn |
| Sep 30, 2022 | 14.56 Bn |
| Jun 30, 2022 | 15.18 Bn |
| Mar 31, 2022 | 13.82 Bn |
| Dec 31, 2021 | 14.89 Bn |
| Sep 30, 2021 | 14.92 Bn |
| Jun 30, 2021 | 14.99 Bn |
| Mar 31, 2021 | 12.52 Bn |
| Dec 31, 2020 | 13.00 Bn |
| Sep 30, 2020 | 8.33 Bn |
| Jun 30, 2020 | 8.21 Bn |
| Mar 31, 2020 | 7.36 Bn |
| Dec 31, 2019 | 7.34 Bn |
| Sep 30, 2019 | 6.96 Bn |
| Jun 30, 2019 | 6.79 Bn |
| Mar 31, 2019 | 4.65 Bn |
| Dec 31, 2018 | 4.48 Bn |
| Sep 30, 2018 | 15.72 Bn |
| Jun 30, 2018 | 15.54 Bn |
| Mar 31, 2018 | 15.52 Bn |
| Dec 31, 2017 | 4.53 Bn |
| Sep 30, 2017 | 9.00 Bn |
| Jun 30, 2017 | 8.52 Bn |
| Mar 31, 2017 | 8.50 Bn |
| Dec 31, 2016 | 8.35 Bn |
| Sep 30, 2016 | 7.65 Bn |
| Jun 30, 2016 | 7.79 Bn |
| Mar 31, 2016 | 3.51 Bn |
| Dec 31, 2015 | 3.70 Bn |
| Sep 30, 2015 | 3.80 Bn |
| Jun 30, 2015 | 3.92 Bn |
| Mar 31, 2015 | 3.59 Bn |
| Dec 31, 2014 | 3.68 Bn |
| Sep 30, 2014 | 2.71 Bn |
| Jun 30, 2014 | 3.04 Bn |
| Mar 31, 2014 | 3.36 Bn |
| Dec 31, 2013 | 1.34 Bn |
| Sep 30, 2013 | 3.43 Bn |
| Jun 30, 2013 | 3.22 Bn |
| Mar 31, 2013 | 2.85 Bn |
| Dec 31, 2012 | 900.00 Mn |